Shamburg News · 8-K filed Nov 16, 2026, 7:09 AM EST
Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Update
PRLD · Prelude Therapeutics Inc
- Earnings
- Reg FD disclosure
- Materiality: high
Prelude Therapeutics reported a net loss of $12.5 million, or $0.12 per share, for the three months ended September 30, 2026, compared with a net loss of $19.7 million, or $0.26 per share, a year earlier. Revenue was $5.6 million versus $6.5 million in the prior-year period, and R&D expense decreased to $14.8 million from $21.7 million. Cash, cash equivalents, restricted cash and marketable securities were $142.7 million as of September 30, 2026, which the company expects will fund operations into the second quarter of 2028.
Source: SEC EDGAR, Form 8-K, Items 2.02, 7.01, accession 0001193125-26-462029.
Written from the filing by Shamburg Markets. Figures are as reported by the company.